- Home
- ADAP vs IGA Comparison
ADAP vs IGA Comparison
Compare ADAP & IGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- IGA
- Stock Information
- Founded
- ADAP 2008
- IGA 2005
- Country
- ADAP United Kingdom
- IGA United States
- Employees
- ADAP N/A
- IGA N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- IGA Investment Managers
- Sector
- ADAP Health Care
- IGA Finance
- Exchange
- ADAP Nasdaq
- IGA Nasdaq
- Market Cap
- ADAP 158.6M
- IGA 147.6M
- IPO Year
- ADAP 2015
- IGA N/A
- Fundamental
- Price
- ADAP $0.58
- IGA $9.48
- Analyst Decision
- ADAP Strong Buy
- IGA
- Analyst Count
- ADAP 4
- IGA 0
- Target Price
- ADAP $2.79
- IGA N/A
- AVG Volume (30 Days)
- ADAP 2.3M
- IGA 42.3K
- Earning Date
- ADAP 03-05-2025
- IGA 01-01-0001
- Dividend Yield
- ADAP N/A
- IGA 8.93%
- EPS Growth
- ADAP N/A
- IGA N/A
- EPS
- ADAP N/A
- IGA N/A
- Revenue
- ADAP $175,041,000.00
- IGA N/A
- Revenue This Year
- ADAP $204.91
- IGA N/A
- Revenue Next Year
- ADAP N/A
- IGA N/A
- P/E Ratio
- ADAP N/A
- IGA N/A
- Revenue Growth
- ADAP 146.27
- IGA N/A
- 52 Week Low
- ADAP $0.53
- IGA $7.77
- 52 Week High
- ADAP $2.05
- IGA $8.88
- Technical
- Relative Strength Index (RSI)
- ADAP 41.87
- IGA 58.41
- Support Level
- ADAP $0.55
- IGA $9.11
- Resistance Level
- ADAP $0.65
- IGA $9.49
- Average True Range (ATR)
- ADAP 0.05
- IGA 0.15
- MACD
- ADAP 0.00
- IGA 0.03
- Stochastic Oscillator
- ADAP 31.31
- IGA 82.22
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About IGA Voya Global Advantage and Premium Opportunity Fund of Beneficial Interest
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategy.